title: Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study.
abstract: Alterations in serum and membrane lipids may be involved in schizophrenia pathophysiology. It is not known whether lipid profiles are associated with disease severity or current symptom level.
  
  
  
  Clinical and lipid data were gathered from 55 patients with schizophrenia admitted to psychiatric emergency wards in an acute stage of the disease (T1). The patients were re-examined after 5 years at a stable phase (T2). The clinical assessments included Positive and Negative Syndrome Scale (PANSS total, positive, negative) and Global Assessment of Functioning (GAF S, symptom and F, function). Serum lipids (cholesterol and triglyceride) and membrane polyunsaturated fatty acids (PUFA, LCPUFA) were measured. Healthy controls were recruited among hospital workers.
  
  
  
  Serum triglyceride was significantly higher in patients with schizophrenia compared to healthy controls both at T1 and T2 (p < 0.001), while serum cholesterol did not differ significantly. The levels of serum lipids in patients remained stable over time. At T1, serum lipids and symptoms were not significantly correlated. At T2, higher serum lipids were associated with more severe symptoms and poorer functioning. Higher serum lipid levels at T1 were associated with more severe symptoms and poorer functioning at T2; cholesterol with GAF-S (p < 0.05), triglyceride with PANSS total (p < 0.05), GAF-S (p < 0.01) and GAF-F (p < 0.01). Membrane lipids were significantly lower in the patient group compared to healthy controls at T1 (PUFA p < 0.001, LCPUFA p < 0.001), but not at T2. Membrane lipids were not significantly correlated with symptoms at T1, but significantly associated with negative symptoms and functioning at T2 as previously reported.
  
  
  
  The present findings suggest different roles of membrane and serum lipids in schizophrenia pathophysiology. To further elucidate the relation of lipid biology to disease traits, replication in independent studies of longitudinal samples are warranted.
authors: Institute for Military Psychiatry, Norwegian Defense Medical Services, Pb 1550 Sentrum, 0015, Oslo, Norway. dagksol@online.no.|Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. dagksol@online.no.
authors: Dag K
authors: 0000-0003-0328-9092
authors: DK
authors: Solberg
authors: Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
authors: Håvard
authors: H
authors: Bentsen
authors: Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
authors: Helge
authors: H
authors: Refsum
authors: NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.|Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
authors: Ole A
authors: OA
authors: Andreassen
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D008297:Male; D008563:Membrane Lipids / Q000097:blood*; D008875:Middle Aged; D010343:Patient Admission / Q000639:trends; D012559:Schizophrenia / Q000097:blood* / Q000175:diagnosis*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
chemical_list: D008055:Lipids; D008563:Membrane Lipids; D014280:Triglycerides; D002784:Cholesterol